ProQR director reports initial share holdings

ProQR Therapeutics N.V. director Shannon James Samuel filed an initial Form 3 reporting his equity holdings in the company.

Rhea-AI Filing Summary

ProQR Therapeutics N.V. director Shannon James Samuel filed an initial Form 3 reporting his equity holdings in the company. The filing lists multiple employee share options over ordinary shares with exercise prices ranging from $1.9800 to $15.7800 and expirations between 2026 and 2035, along with directly held ordinary shares.

The Form 3 shows direct ownership of 61,538 ordinary shares of ProQR Therapeutics and a series of vested and time-vested options that continue to vest in quarterly installments, subject to his continuous service with the company.

Insider Trade Summary

12 transactions reported

Mixed 12 txns

Insider Shannon James Samuel

Role Director

Type	Security	Shares	Price	Value
holding	Share Option (Right to Buy)	--	--	--
holding	Share Option (Right to Buy)	--	--	--
holding	Share Option (Right to Buy)	--	--	--
holding	Share Option (Right to Buy)	--	--	--
holding	Share Option (Right to Buy)	--	--	--
holding	Share Option (Right to Buy)	--	--	--
holding	Share Option (Right to Buy)	--	--	--
holding	Share Option (Right to Buy)	--	--	--
holding	Share Option (Right to Buy)	--	--	--
holding	Share Option (Right to Buy)	--	--	--
holding	Share Option (Right to Buy)	--	--	--
holding	Ordinary Shares	--	--	--

Holdings After Transaction: Share Option (Right to Buy) — 272,853 contracts (Direct); Ordinary Shares — 61,538 shares (Direct)

Footnotes (5)

1. F1. Fully vested.
2. F2. 25% of the shares subject to such option vest and become exercisable on January 1, 2024, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
3. F3. 25% of the shares subject to such option vest and become exercisable on January 1, 2025, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
4. F4. 25% of the shares subject to such option vest and become exercisable on January 1, 2026, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
5. F5. 25% of the shares subject to such option vest and become exercisable on January 1, 2027, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the ProQR (PRQR) Form 3 filing by Shannon James Samuel report?

The Form 3 reports director Shannon James Samuel’s initial ownership in ProQR. It lists his directly held ordinary shares and multiple employee share options over ordinary shares with specified exercise prices and expiration dates, establishing his starting equity position as an insider.

How many ProQR (PRQR) ordinary shares does Shannon James Samuel hold directly?

Shannon James Samuel holds 61,538 ordinary shares of ProQR directly. This direct share position is reported alongside several option grants, giving investors a clearer view of his current common stock stake in the company.

What types of equity awards are disclosed for Shannon James Samuel in ProQR’s Form 3?

The filing discloses multiple Share Option (Right to Buy) awards over ProQR ordinary shares. Each option series has its own exercise price, expiration date and underlying share amount, reflecting a typical mix of fully vested and time-based vesting schedules.

Over what period do Shannon James Samuel’s ProQR share options vest?

Several option grants vest with 25% becoming exercisable on specific January 1 dates from 2024 through 2027. The remaining 75% for each grant vests in 12 substantially equal quarterly installments, contingent on his continuous service with ProQR.

Do the ProQR (PRQR) Form 3 options held by Shannon James Samuel have long-dated expirations?

Yes. The reported share options carry expiration dates ranging from June 20, 2026 through December 31, 2035. These long-dated options give extended potential for future share acquisition if exercised before their respective expiration dates.

Does ProQR’s Form 3 show any recent share purchases or sales by Shannon James Samuel?

No purchases or sales are indicated in this Form 3. The entries are categorized as holdings, summarizing Samuel’s existing ordinary share position and option grants rather than reporting new buy or sell transactions in ProQR stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 04:01 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Shannon James Samuel

(Last) (First) (Middle)

PROQR THERAPEUTICS N.V.

ZERNIKEDREEF 9

(Street)

LEIDEN 2333 CK

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
ProQR Therapeutics N.V. [ PRQR ]

3a. Foreign Trading Symbol
[N/A]

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	61,538	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	(1)	06/20/2026	Ordinary Shares	33,069	$4.89	D
Share Option (Right to Buy)	(1)	12/31/2026	Ordinary Shares	32,164	$4.9	D
Share Option (Right to Buy)	(1)	12/31/2027	Ordinary Shares	27,500	$3.3	D
Share Option (Right to Buy)	(1)	12/31/2028	Ordinary Shares	14,918	$15.78	D
Share Option (Right to Buy)	(1)	12/31/2029	Ordinary Shares	24,615	$9.91	D
Share Option (Right to Buy)	(1)	12/31/2030	Ordinary Shares	23,239	$4.2	D
Share Option (Right to Buy)	(1)	02/29/2032	Ordinary Shares	23,931	$8.01	D
Share Option (Right to Buy)	(2)	12/31/2032	Ordinary Shares	22,608	$3.41	D
Share Option (Right to Buy)	(3)	12/31/2033	Ordinary Shares	23,489	$1.98	D
Share Option (Right to Buy)	(4)	12/31/2034	Ordinary Shares	22,128	$2.65	D
Share Option (Right to Buy)	(5)	12/31/2035	Ordinary Shares	25,192	$2.02	D

Explanation of Responses:

1. Fully vested.

2. 25% of the shares subject to such option vest and become exercisable on January 1, 2024, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

3. 25% of the shares subject to such option vest and become exercisable on January 1, 2025, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

4. 25% of the shares subject to such option vest and become exercisable on January 1, 2026, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

5. 25% of the shares subject to such option vest and become exercisable on January 1, 2027, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Pieter Erik de Ridders, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)